Beam Therapeutics Inc. (BEAM)

Every figure this model derived for BEAM, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 13,391,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 1,152,927,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 1,178,595,000 AssetsCurrent 2026-06-30
current liabilities 80,883,000 LiabilitiesCurrent 2026-06-30
equity 1,067,442,000 StockholdersEquity 2026-06-30
interest expense 0 InterestPaidNet 2025-12-31
ocf -359,377,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 156,035,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 81,517,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up BEAM on one particular measure came for.

RatioValue
cash operating margin-175.77
current ratio14.57
current ratio reported14.57
deferred revenue growth-100.0
dilution pct20.17
fcf margin-238.9
growth cv1.99
operating margin-242.27
owner earnings margin-291.14
revenue growth158.88
revenue growth per share115.43
roic-2021.52
rule of 40-83.38
sbc pct revenue52.24

What to be careful about

What this model itself distrusts about BEAM's figures. Written by the derivation as it ran, not added afterwards.